Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

TACROLIMUS MONOHYDRATE CRS (80 MG)

TACROLIMUS MONOHYDRATE CRS (80 MG)

109581-93-3

DISCOVER
TYLOSIN PHOSPHATE CRS (10 MG)

TYLOSIN PHOSPHATE CRS (10 MG)

ND

DISCOVER
TYLOSIN TARTRATE CRS (10 MG)

TYLOSIN TARTRATE CRS (10 MG)

ND

DISCOVER
TIOTROPIUM FOR SYSTEM SUITABILITY 1 CRS (10 MG)

TIOTROPIUM FOR SYSTEM SUITABILITY 1 CRS (10 MG)

139404-48-1

DISCOVER
MINOCYCLINE HYDROCHLORIDE CRS(100 MG)

MINOCYCLINE HYDROCHLORIDE CRS(100 MG)

13614-98-7

DISCOVER
QUERCITRIN CRS (15 MG)

QUERCITRIN CRS (15 MG)

ND

DISCOVER
SAIKOSAPONIN A CRS (25 MG)

SAIKOSAPONIN A CRS (25 MG)

ND

DISCOVER
TACROLIMUS FOR SYSTEM SUITABILITY CRS (10 MG)

TACROLIMUS FOR SYSTEM SUITABILITY CRS (10 MG)

NA

DISCOVER
DEFEROXAMINE FOR SYSTEM SUITABILITY CRS (15 MG)

DEFEROXAMINE FOR SYSTEM SUITABILITY CRS (15 MG)

NA

DISCOVER
GREEN TEA DRY EXTRACT HRS (110 MG)

GREEN TEA DRY EXTRACT HRS (110 MG)

ND

DISCOVER
(-)-EPIGALLOCATECHIN-3-O- GALLATE CRS (50 MG)

(-)-EPIGALLOCATECHIN-3-O- GALLATE CRS (50 MG)

ND

DISCOVER
DEFEROXAMINE FOR PEAK IDENTIFICATION CRS (20 MG)

DEFEROXAMINE FOR PEAK IDENTIFICATION CRS (20 MG)

NA

DISCOVER